NewAmsterdam Pharma Company N.V. Ordinary Shares Total Assets
NewAmsterdam Pharma Company N.V. Ordinary Shares total assets. Based on the latest financial reports, NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) holds total assets worth $786.43 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is NewAmsterdam Pharma Company N.V. Ordinar worth for the company's overall valuation and market capitalisation.
Total Assets of NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
Total assets of NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2024. This chart illustrates how NewAmsterdam Pharma Company N.V. Ordinary Shares's total assets have evolved over time, based on quarterly financial data. See today's stock price for NewAmsterdam Pharma Company N.V. Ordinar for real-time trading data and today's change.
NewAmsterdam Pharma Company N.V. Ordinary Shares - Asset Composition Analysis
NewAmsterdam Pharma Company N.V. Ordinary Shares Total Assets Breakdown (December 2024)
NewAmsterdam Pharma Company N.V. Ordinary Shares total assets breakdown as of December 2024. NewAmsterdam Pharma Company N.V. Ordinary Shares's total assets of $786.43 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.3% |
| Accounts Receivable | $21.30 Million | 2.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $534.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how NewAmsterdam Pharma Company N.V. Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NewAmsterdam Pharma Company N.V. Ordinar current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NewAmsterdam Pharma Company N.V. Ordinary Shares's current assets represent 99.9% of total assets in 2024, an increase from 1.3% in 2020.
- Cash Position: Cash and equivalents constituted 89.3% of total assets in 2024, up from 1.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 2.5% of total assets.
NewAmsterdam Pharma Company N.V. Ordinary Shares Competitors by Total Assets
Key competitors of NewAmsterdam Pharma Company N.V. Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
NewAmsterdam Pharma Company N.V. Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.57 | 10.61 | 0.72 |
| Quick Ratio | 12.57 | 10.74 | 0.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $674.06 Million | $396.62 Million | $-897.25K |
NewAmsterdam Pharma Company N.V. Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between NewAmsterdam Pharma Company N.V. Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.35 |
| Latest Market Cap to Assets Ratio | 2.63 |
| Asset Growth Rate (YoY) | 149.1% |
| Total Assets | $864.62 Million |
| Market Capitalization | $2.27 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values NewAmsterdam Pharma Company N.V. Ordinary Shares's assets at a significant premium (2.63x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: NewAmsterdam Pharma Company N.V. Ordinary Shares's assets grew by 149.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
The table below shows the annual total assets of NewAmsterdam Pharma Company N.V. Ordinary Shares from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $864.62 Million | +149.10% |
| 2023-12-31 | $347.10 Million | -27.46% |
| 2022-12-31 | $478.50 Million | +603.79% |
| 2021-12-31 | $67.99 Million | -51.39% |
| 2020-12-31 | $139.87 Million | -- |
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more